Latest Insider Transactions at International Flavors & Fragrances Inc (IFF)
This section provides a real-time view of insider transactions for International Flavors & Fragrances Inc (IFF). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INTERNATIONAL FLAVORS & FRAGRANCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INTERNATIONAL FLAVORS & FRAGRANCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2025
|
Kevin O'Byrne Director |
BUY
Open market or private purchase
|
Indirect |
6,500
+50.0%
|
$520,000
$80.44 P/Share
|
|
Mar 04
2025
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
123
-0.52%
|
$9,717
$79.79 P/Share
|
|
Mar 04
2025
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
BUY
Grant, award, or other acquisition
|
Direct |
269
+1.13%
|
-
|
|
Mar 04
2025
|
Michael De Veau CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
42
-0.51%
|
$3,318
$79.79 P/Share
|
|
Mar 04
2025
|
Michael De Veau CFO |
BUY
Grant, award, or other acquisition
|
Direct |
101
+1.21%
|
-
|
|
Mar 04
2025
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
86
-0.79%
|
$6,794
$79.79 P/Share
|
|
Mar 04
2025
|
Simon Herriott Pres. Health & Bioscience |
BUY
Grant, award, or other acquisition
|
Direct |
237
+2.14%
|
-
|
|
Mar 04
2025
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-1.05%
|
$6,083
$79.79 P/Share
|
|
Mar 04
2025
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
186
+2.47%
|
-
|
|
Mar 04
2025
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
34
-0.39%
|
$2,686
$79.79 P/Share
|
|
Mar 04
2025
|
Angela Strzelecki President, Pharma Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
96
+1.1%
|
-
|
|
Mar 04
2025
|
De Mendonca Ana Paula Teles President, Scent |
SELL
Payment of exercise price or tax liability
|
Direct |
15
-1.58%
|
$1,185
$79.79 P/Share
|
|
Mar 04
2025
|
De Mendonca Ana Paula Teles President, Scent |
BUY
Grant, award, or other acquisition
|
Direct |
35
+3.55%
|
-
|
|
Mar 04
2025
|
J Erik Fyrwald CEO |
BUY
Open market or private purchase
|
Direct |
25,000
+46.04%
|
$2,000,000
$80.24 P/Share
|
|
Jan 15
2025
|
Beril Yildiz CAO, SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,340
-22.67%
|
$112,560
$84.17 P/Share
|
|
Jan 15
2025
|
Beril Yildiz CAO, SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
3,976
+40.21%
|
-
|
|
Dec 02
2024
|
Ralf Finzel EVP, Global Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,943
-20.19%
|
$176,813
$91.27 P/Share
|
|
Dec 02
2024
|
Ralf Finzel EVP, Global Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,387
+35.89%
|
-
|
|
Nov 11
2024
|
Yuvraj Arora President, Nourish |
SELL
Open market or private sale
|
Direct |
5,000
-60.69%
|
$455,000
$91.75 P/Share
|
|
Oct 03
2024
|
Beril Yildiz CAO, SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
389
-16.74%
|
$38,900
$100.63 P/Share
|
|
Oct 03
2024
|
Beril Yildiz CAO, SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,078
+31.69%
|
-
|
|
Oct 01
2024
|
Glenn R Richter CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,122
-15.92%
|
$527,566
$103.12 P/Share
|
|
Oct 01
2024
|
Glenn R Richter CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,812
+26.86%
|
-
|
|
Sep 03
2024
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,049
-12.03%
|
$726,047
$103.58 P/Share
|
|
Sep 03
2024
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,807
+18.1%
|
-
|
|
Jul 03
2024
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
289
-2.69%
|
$27,455
$95.02 P/Share
|
|
Jul 03
2024
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
627
+5.51%
|
-
|
|
Jun 13
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Open market or private sale
|
Direct |
2,588
-23.26%
|
$245,860
$95.66 P/Share
|
|
Jun 13
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
2,588
+18.87%
|
$199,276
$77.16 P/Share
|
|
May 06
2024
|
De Mendonca Ana Paula Teles President, Scent |
SELL
Payment of exercise price or tax liability
|
Direct |
262
-22.24%
|
$23,056
$88.66 P/Share
|
|
May 06
2024
|
De Mendonca Ana Paula Teles President, Scent |
BUY
Exercise of conversion of derivative security
|
Direct |
726
+38.13%
|
-
|
|
May 03
2024
|
Gaoxiang Hu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+44.25%
|
-
|
|
May 03
2024
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
765
-9.64%
|
$65,790
$86.64 P/Share
|
|
May 03
2024
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,121
+21.09%
|
-
|
|
May 03
2024
|
Glenn R Richter CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,530
-6.99%
|
$131,580
$86.64 P/Share
|
|
May 03
2024
|
Glenn R Richter CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,243
+16.24%
|
-
|
|
May 03
2024
|
De Mendonca Ana Paula Teles President, Scent |
SELL
Payment of exercise price or tax liability
|
Direct |
255
-36.07%
|
$21,930
$86.64 P/Share
|
|
May 03
2024
|
De Mendonca Ana Paula Teles President, Scent |
BUY
Exercise of conversion of derivative security
|
Direct |
707
+50.0%
|
-
|
|
May 03
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
329
-3.71%
|
$28,294
$86.64 P/Share
|
|
May 03
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
1,060
+10.68%
|
-
|
|
May 03
2024
|
Kevin O'Byrne Director |
SELL
Payment of exercise price or tax liability
|
Direct |
218
-11.28%
|
$18,748
$86.64 P/Share
|
|
May 03
2024
|
Kevin O'Byrne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+46.37%
|
-
|
|
May 03
2024
|
Beril Yildiz CAO, SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-21.54%
|
$29,412
$86.64 P/Share
|
|
May 03
2024
|
Beril Yildiz CAO, SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
848
+34.81%
|
-
|
|
May 03
2024
|
Ralf Finzel EVP, Global Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
535
-11.22%
|
$46,010
$86.64 P/Share
|
|
May 03
2024
|
Ralf Finzel EVP, Global Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,326
+21.75%
|
-
|
|
May 03
2024
|
Christina A Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+13.36%
|
-
|
|
May 03
2024
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
493
-4.64%
|
$42,398
$86.64 P/Share
|
|
May 03
2024
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
1,591
+13.02%
|
-
|
|
May 03
2024
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
713
-4.15%
|
$61,318
$86.64 P/Share
|